News | November 02, 2008

LifeNet Health Receives FDA Clearance for New Cardiovascular Technology

November 3, 2008 - LifeNet Health received 510(k) clearance from the FDA for CardioGraft allograft cardiac patch products with MatrACELL decellularization technology.

LifeNet Health received clearance for the technology for cardiac products, which safely removes donor cells from cardiovascular tissues while retaining the native biomechanical strength of the tissue.

The company said the clearance strengthens LifeNet Health’s position in the pediatric cardiac reconstruction market.

LifeNet Health, founded in 1982, is a full-service biomedical tissue banking system and a leading non-profit organ and tissue donation agency. It provides recovery and processing services for musculoskeletal and cardiovascular tissues, distributing more than 250,000 biomedical implants every year to restore health to patients around the world.

For more information: www.lifenethealth.org


Additional Content

News | Cardiovascular Surgery

May 4, 2026 — Johnson & Johnson recently announced new data from a novel U.S. pilot single-arm trial that evaluated the ...

Home May 05, 2026
Home
News | Cardiovascular Surgery

March 24, 2026 — iPerf, a company specializing in the development of medical devices for cardiopulmonary support, has ...

Home March 25, 2026
Home
News | Cardiovascular Surgery

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Home February 13, 2026
Home
News | Cardiovascular Surgery

Feb. 11, 2026 – Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery ...

Home February 12, 2026
Home
News | Cardiovascular Surgery

Feb. 6, 2026 — Robert Wood Johnson University Hospital (RWJUH), in partnership with Rutgers Robert Wood Johnson Medical ...

Home February 06, 2026
Home
Subscribe Now